Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CMBI Raises WUXI XDC's TP to HKD88 w/ Rating Reiterated Buy; Earnings Expected to Grow Strongly
Recommend 1 Positive 5 Negative 0 |
||||
|
||||
|
WUXI XDC (02268.HK) has issued a positive profit alert projecting its 2025 revenue/ net profit to have grown by at least 45%/ over 38% YoY, according to CMBI's research report. The adjusted net profit, meanwhile, is expected to have risen by over 45%. It could even reach over 65% if excluding foreign exchange effects. CMBI has raised its target price on WUXI XDC from HKD74 to HKD88 and kept the Buy rating unchanged. It anticipates the drugmaker to see its 2025-27 revenue soar by 45.7%/ 36.6%/ 31.7% YoY and its adjusted net profit increase by 34.9%/ 38.4%/ 32.9%. These forecasts do not reflect the impact of the BioDlink acquisition. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
